Archit Organosys

Which are the latest news on Archit Organosys?

Why is Archit Organosys Ltd falling/rising?

As of 05-Sep, Archit Organosys Ltd's stock price has fallen to Rs 62.14, a decrease of 4.69% after five days of gains, indicating a trend reversal. Despite this decline, the stock has performed well over the past year, with a return of 31.54%, but is currently experiencing a correction.

As of 05-Sep, Archit Organosys Ltd's stock price is falling, currently at Rs 62.14, which reflects a decrease of Rs 3.06 or 4.69%. This decline comes after a period of five consecutive days of gains, indicating a trend reversal. Additionally, the stock has underperformed its sector by 1.19% today. Despite this drop, the stock remains close to its 52-week high, just 2.17% away from Rs 66.<BR><BR>In the context of broader performance, the stock has shown a positive trajectory over the past year, generating a return of 31.54%, significantly outperforming the market's average return of 1.51%. However, the recent price movement suggests that the stock is experiencing a correction after its previous gains. Furthermore, while the stock is trading above its moving averages, the current decline may reflect profit-taking by investors after a strong performance.

Who are in the management team of Archit Organosys?

The management team of Archit Organosys includes Kandarp K Amin (Chairman & Wholetime Director), Archana K Amin (Whole-time Director), Bhupendra Mehta and Rajendraprasad J Shah (Non-Executive & Independent Directors), Archit Amin (Whole-time Director), Anchal Bansal and Vijay A. Boliya (Company Secretaries), Shreeraj Desai (Additional Non-Executive & Independent Director), and Nikul Jagdishchandra Patel (Additional Director). They oversee the company's operations and strategic direction.

The management team of Archit Organosys includes the following members:<BR><BR>1. **Kandarp K Amin** - Chairman & Wholetime Director<BR>2. **Archana K Amin** - Whole-time Director<BR>3. **Bhupendra Mehta** - Non-Executive & Independent Director<BR>4. **Rajendraprasad J Shah** - Non-Executive & Independent Director<BR>5. **Archit Amin** - Whole-time Director<BR>6. **Anchal Bansal** - Company Secretary<BR>7. **Shreeraj Desai** - Additional Non-Executive & Independent Director<BR>8. **Nikul Jagdishchandra Patel** - Additional Director<BR>9. **Vijay A. Boliya** - Company Secretary<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Archit Organosys do?

Archit Organosys Ltd manufactures and trades chemical products in the commodity chemicals industry. As of June 2026, it reported net sales of 37 Cr and a net profit of 1 Cr, with a market cap of INR 132 Cr.

Overview: <BR>Archit Organosys Ltd is engaged in the manufacturing and trading of various chemical products within the commodity chemicals industry and operates as a micro-cap company.<BR><BR>History: <BR>The company was originally incorporated on 4th August 1993 as "Shri Chlochem Limited" and changed its name to Archit Organosys Limited on 19th May 2012. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 37 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 132 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 210.00 <BR>Industry P/E: 43 <BR>Dividend Yield: 0.79% <BR>Debt-Equity: 0.30 <BR>Return on Equity: 9.76% <BR>Price to Book: 1.71 <BR><BR>Contact Details: <BR>Address: Plot No 25/9/A Phase III, G I D C Naroda Ahmedabad Gujarat : 382330 <BR>Tel: 91-079-2821154 <BR>Email: share@architorg.com <BR>Website: http://www.architorg.com

Who are the peers of the Archit Organosys?

Peers of Archit Organosys include IVP, ARCL Organics, ZR2 Bioenergy, Kanchi Karpooram, Kesar Petroprod., Sh. Hari Chem., AG Ventures, Polychem, and Ritesh Intl. Sh. Hari Chem. leads in 1-year returns at 101.43%, while Archit Organosys has a return of 43.29%.

Peers: The peers of Archit Organosys are IVP, ARCL Organics, ZR2 Bioenergy, Kanchi Karpooram, Kesar Petroprod., Sh. Hari Chem., AG Ventures, Polychem, and Ritesh Intl.<BR><BR>Quality Snapshot: Excellent management risk is observed at ARCL Organics and Polychem, while Average management risk is found at IVP, Kanchi Karpooram, Sh. Hari Chem., and Ritesh Intl., and the rest have Below Average management risk. Good growth is noted at ARCL Organics, Sh. Hari Chem., and Kesar Petroprod., while Average growth is seen at Kanchi Karpooram and Polychem, and the rest have Below Average growth. Excellent capital structure is present at Kanchi Karpooram and AG Ventures, while Average capital structure is found at Archit Organosys and Ritesh Intl., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sh. Hari Chem. at 101.43%, while ZR2 Bioenergy has the lowest at -70.89%. Archit Organosys has a 1-year return of 43.29%, which is significantly higher than ZR2 Bioenergy but lower than Sh. Hari Chem. Additionally, Kesar Petroprod. and AG Ventures have negative six-month returns.

How big is Archit Organosys?

Summary could not be generated.

As of 31st August, Archit Organosys Ltd has a market capitalization of 132.00 Cr, classified as a Micro Cap company.<BR><BR>In the latest four quarters, Archit Organosys reported net sales of 113.19 Cr and a net profit of 3.27 Cr.<BR><BR>The reporting period for the balance sheet is the latest annual period, but data for Shareholder's Funds and Total Assets is unavailable.

Should I buy, sell or hold Archit Organosys Ltd?

When is the next results date for Archit Organosys Ltd?

The next results date for Archit Organosys Ltd is 16 May 2026.

The next results date for Archit Organosys Ltd is scheduled for 16 May 2026.

Are Archit Organosys Ltd latest results good or bad?

Archit Organosys Ltd's latest results show a significant profit increase of 628.93% for Q3 FY26, but concerns remain due to declining operating margins and a low return on equity of 0.97%. Investors should consider these mixed signals when evaluating the company's financial health.

Archit Organosys Ltd's latest results present a mixed picture. On one hand, the company achieved a significant turnaround in net profit for Q3 FY26, reporting ₹2.43 crores, which marks a remarkable 628.93% increase quarter-on-quarter. Additionally, revenue growth for the first half of FY26 was robust at 28.60% compared to the same period last year, indicating strong top-line performance.<BR><BR>However, there are notable concerns regarding profitability and operational efficiency. The operating margin has decreased to 7.69%, down from 10.48% in the previous quarter, reflecting ongoing margin compression. Furthermore, the return on equity (ROE) is critically low at just 0.97%, suggesting that the company is struggling to generate adequate returns for shareholders.<BR><BR>Overall, while the recent profit increase is encouraging, the underlying issues of declining margins and poor capital efficiency raise significant red flags. Investors should weigh these factors carefully when assessing the company's financial health and future prospects.

Is Archit Organosys overvalued or undervalued?

As of November 13, 2025, Archit Organosys is considered overvalued with a PE ratio of 147.70, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -6.00%.

As of 13 November 2025, Archit Organosys' valuation grade has moved from attractive to fair. The company appears to be overvalued based on its current metrics. Notable ratios include a PE ratio of 147.70, an EV to EBITDA of 18.19, and a PEG ratio of 0.01, which suggests a significant disparity in growth expectations relative to its price.<BR><BR>In comparison to peers, Archit Organosys' PE ratio is substantially higher than that of Godrej Industries at 37.09, which is rated attractive, and Aarti Industries at 53.04, also rated fair. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -6.00% compared to the Sensex's 8.11%, further reinforcing the notion that Archit Organosys is currently overvalued.

How has been the historical performance of Archit Organosys?

Archit Organosys has experienced a declining trend in net sales and profits, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr in the same period. Key financial metrics indicate a challenging performance, highlighted by a significant reduction in operating profit margin and earnings per share.

Answer:<BR>The historical performance of Archit Organosys shows a declining trend in net sales and profits over the past few years.<BR><BR>Breakdown:<BR>Archit Organosys reported net sales of 113.19 Cr in March 2024, a decrease from 127.78 Cr in March 2023 and 137.90 Cr in March 2022. The total operating income mirrored this decline, remaining at 113.19 Cr in March 2024 compared to 127.78 Cr in the previous year. The total expenditure, excluding depreciation, also decreased to 106.45 Cr in March 2024 from 108.90 Cr in March 2023. Operating profit (PBDIT) fell significantly to 9.18 Cr in March 2024 from 20.74 Cr in March 2023, reflecting a decrease in the operating profit margin from 14.78% to 5.95%. Profit before tax dropped to 4.32 Cr in March 2024, down from 15.36 Cr in March 2023, leading to a profit after tax of 3.28 Cr compared to 11.35 Cr the previous year. The earnings per share also declined to 1.6 in March 2024 from 5.53 in March 2023. Overall, the financial metrics indicate a challenging period for Archit Organosys, with declining revenues and profits over the years.

Who are the top shareholders of the Archit Organosys?

The top shareholder of Archit Organosys is Archana Kandarp Amin, holding 22.44%. Individual investors own 30.78% of the company, with Shamoil Plumber as the largest public shareholder at 1.19%.

The top shareholders of Archit Organosys are primarily the promoters, with Archana Kandarp Amin holding the highest stake at 22.44%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) currently holding shares. Additionally, individual investors collectively own 30.78% of the company, with the highest public shareholder being Shamoil Plumber, who holds 1.19%.

What is the technical trend for Archit Organosys?

As of May 12, 2025, Archit Organosys shows a mildly bearish trend overall, with mixed signals from MACD and moving averages indicating short-term weakness despite some bullish signs on the weekly chart.

As of 12 May 2025, the technical trend for Archit Organosys has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands show a bullish signal on the weekly chart but are mildly bearish on the monthly. Daily moving averages are mildly bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly but bearish on the monthly, and Dow Theory shows a mildly bullish trend on the weekly with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and moving averages.

Has Archit Organosys declared dividend?

Yes, Archit Organosys Ltd has declared a 5% dividend, amounting to ₹0.5 per share, with an ex-date of August 8, 2023. The current dividend yield is 0%, and total returns have varied significantly across different periods, with a notable increase of 333.44% over the past five years.

Archit Organosys Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 08 Aug 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -4.8%, the dividend return was 0%, resulting in a total return of -4.8%.<BR><BR>In the 1-year period, the price return was 6.78%, the dividend return was 0%, leading to a total return of 6.78%.<BR><BR>For the 2-year period, the price return was -34.63%, the dividend return was 0.80%, culminating in a total return of -33.83%.<BR><BR>During the 3-year period, the price return was -6.83%, the dividend return was 2.90%, resulting in a total return of -3.93%.<BR><BR>In the 4-year period, the price return was -0.25%, the dividend return was 4.11%, leading to a total return of 3.86%.<BR><BR>Over the 5-year period, the price return was 317.05%, the dividend return was 16.39%, resulting in a total return of 333.44%.<BR><BR>Overall, Archit Organosys has declared a dividend, but the dividend yield is currently at 0%. The total returns show significant variability, with a notable increase over the 5-year period, contrasting with the negative returns in shorter time frames.